The recombinant anti-EGF receptor immunotoxin 425(scFv)-ETA' suppresses growth of a highly metastatic pancreatic carcinoma cell line
- PMID: 12964002
- DOI: 10.3892/ijo.23.4.1179
The recombinant anti-EGF receptor immunotoxin 425(scFv)-ETA' suppresses growth of a highly metastatic pancreatic carcinoma cell line
Abstract
Pancreatic carcinoma still has the highest mortality rate in comparison to any other malignancy. Major reasons are late detection of disease, highly aggressive tumor growth and the early formation of metastases. Thus, novel effective therapies are urgently needed to improve the outcome of the patients. Overexpression of the epidermal growth factor receptor (EGFR) and its ligands has been implicated in the oncogenesis of pancreatic carcinoma and associated with an unfavorable prognosis. Consequently, the EGFR represents a specific target antigen suitable for immunotherapy. We generated a recombinant immunotoxin by fusing the anti-EGFR single chain fragment 425(scFv) to a truncated mutant of Pseudomonas Exotoxin A (ETA'). Using the expression vector pBM1.1, functional 425(scFv)-ETA' was periplasmically expressed under osmotic stress conditions in the presence of compatible solutes. The 72 kDa His10-tagged fusion protein was purified by a combination of metal-ion affinity and molecular size chromatography. Binding activity and specificity of the immunotoxin to the EGFR-positive pancreatic carcinoma cell line L3.6pl was confirmed by flow cytometry and ELISA. Finally, 425(scFv)-ETA' showed significant toxicity toward this cell line reaching 50% inhibition of cell proliferation at a concentration (IC50) of 7.5 ng/ml. This is the first report documenting the specific cytotoxicity of a recombinant immunotoxin towards metastatic pancreatic carcinoma cells, suggesting that EGFR-specific antibody toxins may become valuable therapeutic reagents for the treatment of pancreatic carcinoma.
Similar articles
-
Recombinant anti-EGFR immunotoxin 425(scFv)-ETA' demonstrates anti-tumor activity against disseminated human pancreatic cancer in nude mice.Int J Mol Med. 2005 Feb;15(2):305-13. Int J Mol Med. 2005. PMID: 15647848
-
Recombinant CD64-specific single chain immunotoxin exhibits specific cytotoxicity against acute myeloid leukemia cells.Cancer Res. 2003 Dec 1;63(23):8414-9. Cancer Res. 2003. PMID: 14679004
-
Construction and in vitro evaluation of RFT5(scFv)-ETA', a new recombinant single-chain immunotoxin with specific cytotoxicity toward CD25+ Hodgkin-derived cell lines.Int J Mol Med. 1998 Jan;1(1):249-56. doi: 10.3892/ijmm.1.1.249. Int J Mol Med. 1998. PMID: 9852227
-
Recombinant anti-CD25 immunotoxin RFT5(SCFV)-ETA' demonstrates successful elimination of disseminated human Hodgkin lymphoma in SCID mice.Int J Cancer. 2000 Jun 1;86(5):718-24. doi: 10.1002/(sici)1097-0215(20000601)86:5<718::aid-ijc18>3.0.co;2-n. Int J Cancer. 2000. PMID: 10797296
-
Immunotoxins in cancer therapy: Review and update.Int Rev Immunol. 2017 Jul 4;36(4):207-219. doi: 10.1080/08830185.2017.1284211. Epub 2017 Mar 1. Int Rev Immunol. 2017. PMID: 28282218 Review.
Cited by
-
Application of advances in endocytosis and membrane trafficking to drug delivery.Adv Drug Deliv Rev. 2020;157:118-141. doi: 10.1016/j.addr.2020.07.026. Epub 2020 Aug 3. Adv Drug Deliv Rev. 2020. PMID: 32758615 Free PMC article. Review.
-
A deimmunized bispecific ligand-directed toxin that shows an impressive anti-pancreatic cancer effect in a systemic nude mouse orthotopic model.Pancreas. 2012 Jul;41(5):789-96. doi: 10.1097/MPA.0b013e31823b5f2e. Pancreas. 2012. PMID: 22258068 Free PMC article.
-
In vitro and in vivo anti-tumor activities of anti-EGFR single-chain variable fragment fused with recombinant gelonin toxin.J Cancer Res Clin Oncol. 2012 Jul;138(7):1081-90. doi: 10.1007/s00432-012-1181-7. Epub 2012 Mar 7. J Cancer Res Clin Oncol. 2012. PMID: 22392077
-
Immunotoxins for targeted cancer therapy.AAPS J. 2006 Aug 18;8(3):E532-51. doi: 10.1208/aapsj080363. AAPS J. 2006. PMID: 17025272 Free PMC article. Review.
-
Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR Nanobodies.Cancer Immunol Immunother. 2007 Mar;56(3):303-317. doi: 10.1007/s00262-006-0180-4. Cancer Immunol Immunother. 2007. PMID: 16738850 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous